Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 3Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Terminated 2Completed 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 1Glioblastoma 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24venetoclax 23Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23Azacitidine 23Ipilimumab 22Fluorouracil 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × nintedanib × Clear all
NCT02902484 2024-06-03

Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

University of Texas Southwestern Medical Center

Phase 1/2 Terminated
14 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01666600 2017-11-01

NOA-12: BIBF1120 and R-RT in Glioblastoma

University Hospital Heidelberg

Phase 1/2 Terminated
63 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡